Boston Advisors LLC reduced its stake in Humana Inc. (NYSE:HUM) by 1.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,597 shares of the insurance provider’s stock after selling 35 shares during the period. Boston Advisors LLC’s holdings in Humana were worth $467,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Daiwa SB Investments Ltd. raised its position in shares of Humana by 7.5% in the second quarter. Daiwa SB Investments Ltd. now owns 720 shares of the insurance provider’s stock valued at $132,000 after buying an additional 50 shares during the period. Bessemer Group Inc. raised its position in shares of Humana by 392.6% in the first quarter. Bessemer Group Inc. now owns 1,000 shares of the insurance provider’s stock valued at $183,000 after buying an additional 797 shares during the period. Spark Investment Management LLC acquired a new position in shares of Humana during the first quarter valued at about $274,000. Rehmann Capital Advisory Group raised its position in shares of Humana by 0.4% in the first quarter. Rehmann Capital Advisory Group now owns 1,506 shares of the insurance provider’s stock valued at $276,000 after buying an additional 6 shares during the period. Finally, Trust Co raised its position in shares of Humana by 12.4% in the first quarter. Trust Co now owns 1,720 shares of the insurance provider’s stock valued at $315,000 after buying an additional 190 shares during the period. Institutional investors own 93.24% of the company’s stock.
Shares of Humana Inc. (NYSE:HUM) traded up 0.33% during midday trading on Wednesday, hitting $177.80. 1,040,002 shares of the stock were exchanged. The stock has a 50 day moving average price of $176.90 and a 200-day moving average price of $176.10. Humana Inc. has a 12 month low of $150.00 and a 12 month high of $191.65. The company has a market cap of $26.50 billion, a PE ratio of 27.32 and a beta of 0.90.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, August 3rd. The insurance provider reported $2.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.23 by $0.07. Humana had a net margin of 1.76% and a return on equity of 11.11%. The company earned $14 billion during the quarter, compared to analysts’ expectations of $13.59 billion. During the same quarter last year, the company posted $1.67 EPS. The firm’s revenue was up 2.0% compared to the same quarter last year. On average, analysts predict that Humana Inc. will post $9.24 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 28th. Shareholders of record on Thursday, October 13th will be given a $0.29 dividend. The ex-dividend date is Tuesday, October 11th. This represents a $1.16 annualized dividend and a yield of 0.65%. Humana’s dividend payout ratio is presently 18.18%.
Several analysts have recently weighed in on the stock. Argus reaffirmed a “hold” rating on shares of Humana in a research note on Tuesday, August 23rd. JPMorgan Chase & Co. downgraded shares of Humana from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $196.00 to $150.00 in a research note on Friday, July 8th. RBC Capital Markets reaffirmed a “buy” rating and set a $224.00 price target (up previously from $220.00) on shares of Humana in a research note on Friday, July 22nd. Jefferies Group raised shares of Humana from a “hold” rating to a “buy” rating and lifted their price target for the company from $158.89 to $210.00 in a research note on Monday, July 18th. Finally, Wolfe Research assumed coverage on shares of Humana in a research note on Tuesday, June 28th. They set a “market perform” rating and a $244.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Humana presently has a consensus rating of “Buy” and an average price target of $201.00.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group accounts, as well as individual commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.